Enabling earlier cancer detection with glycosaminoglycan profiling

Pioneering Swedish diagnostics company Elypta aims to prevent cancer mortality by enabling earlier cancer detection. In this video, members of the Elypta leadership team — Chief Executive Officer, Karl Bergman, and Vice President of R&D, Karin Mattsson — discuss innovation in glycosaminoglycan (GAG) extraction and measurement as novel biomarkers for cancer and describe how working closely with Merck* as a contract manufacturing partner has enabled Elypta to produce the first standardized extraction kit for full-spectrum human GAG quantification in body fluids.

*The Life Science business of Merck operates as MilliporeSigma in the U.S. and Canada.